ENDRA Life Sciences Inc (NDRA) USD0.0001
ENDRA Life Sciences Inc. is engaged in commercialization of an enhanced ultrasound technology for the pre-clinical research market. The Company's Nexus 128 system combines light-based thermoacoustics and ultrasound, to address the imaging needs of researchers studying disease models in pre-clinical applications. The Company is involved in developing Thermo Acoustic Enhanced Ultrasound (TAEUS) for incorporation into new ultrasound systems. The TAEUS platform has capabilities and potential clinical applications, such as enabling ultrasound to distinguish fat from lean tissue; enabling traditional ultrasound to visualize changes in tissue temperature, in real time; enabling ultrasound to view blood vessels from any angle, using only a saline solution contrasting agent, unlike Doppler ultrasound which requires precise viewing angles, and enabling ultrasound to image blood flow at the capillary level in a region, organ or tissue.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.